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Background. Recent data suggest that the renin-angiotensin system may be involved in triglyceride (TG) metabolism. We explored
the eﬀect of the common A1166C and C573T polymorphisms of the angiotensin II type 1 receptor (AT1R) gene on postprandial
lipemia.Methods.Eighty-twosubjectsmeasureddaytimecapillaryTG,andpostprandiallipemiawasestimatedasincrementalarea
under the TG curve. The C573T and A1166C polymorphisms of the AT1R gene were determined. Results. Postprandial lipemia
was signiﬁcantly higher in homozygous carriers of the 1166-C allele (9.39 ± 8.36mM∗h/L) compared to homozygous carriers of
the 1166-A allele (2.02 ± 6.20mM∗h/L) (P<0.05). Postprandial lipemia was similar for the diﬀerent C573T polymorphisms.
Conclusion. The 1166-C allele of the AT1R gene seems to be associated with increased postprandial lipemia. These data conﬁrm
the earlier described relationships between the renin-angiotensin axis and triglyceride metabolism.
1.Introduction
Hypertriglyceridemia is an independent risk factor for the
development of cardiovascular disease (CAD) [1, 2]. Recent
prospective studies have shown that nonfasting TG levels
are also associated with an increased risk in cardiovascular
disease [3] and are possibly an even stronger predictor for
CAD than fasting TG considering that humans are mostly
in the nonfasting state [4, 5]. There is increasing interest
to identify genes involved in the regulation of postprandial
lipemia. The classical genes inﬂuencing TG metabolism like
lipoprotein lipase or the APOE receptor are well known, but
several others have been identiﬁed recently [6–8]. The large
individual variability of TG levels cannot be fully explained
by eﬀects of these genes only. Most likely, environmental
and dietary eﬀects are the most important determinants of
TG levels. However, unexpected eﬀects by non-lipid-related
geneshavealsobeendescribed.Thereninangiotensinsystem
mutationalpolymorphismshasbeenrelatedtothemetabolic
syndrome and consequently to hypertriglyceridemia [9]. In
the last decade, the beneﬁcial eﬀect of blockade of the
renin-angiotensin system have been demonstrated in a wide
variety of cardiovascular diseases, from heart failure to stable
coronary artery disease and diabetic as well as nondiabetic
chronic nephropathies [10, 11]. Therefore, the aim of the
present study was to explore possible relationships between
the angiotensin II type 1 receptor (AT1R) polymorphisms,
A1166C and C573T, and fasting and postprandial triglyc-
eridemia.
2.MaterialandMethods
2.1. Subjects. This paper is part of an ongoing study
aimed at evaluating inheritable risk factors for premature
atherosclerosis, metabolic disturbances, and genetic deter-
minants. Normocholesterolemic CAD patients and their
ﬁrst-degree relatives were asked to participate. All CAD
indexpatientshadcoronarysclerosisestablishedbycoronary
angiography at a young age (before the age of 50 in men2 International Journal of Vascular Medicine
a n do f6 0i nw o m e n )a n dh a du n d e r g o n eap e r c u t a n e o u s
transluminal coronary angioplasty (PTCA) at the Heart
Lung Centre Utrecht. Exclusion criteria for index patients
were the presence of diabetes mellitus, body mass index
(BMI) >30kg/m2, renal and/or liver failure, fasting plasma
cholesterol >6.5mmol/L (without lipid lowering medica-
tion), the presence of the apo E2/E2 genotype, the use of
alcohol of more than 3 units a day, and a cardiac event or
revascularization procedure during six months before the
startofthestudy.Lipid-loweringmedication,whichwasused
by ﬁve patients, was stopped for 5 weeks before entering the
study.
Only families of which at least two ﬁrst-degree relatives
were available for analysis were included. Exclusion criteria
for family members were similar to those for the CAD
index patients, except they should not have a medical
history of CAD. Information about subjects’ personal and
family histories of cardiovascular disease was obtained by
a standardised questionnaire. All participants were invited
for a screening visit at the hospital. On the morning of
inclusion blood pressure, weight, length, and waist and hip
circumferenceweremeasuredandafastingbloodsamplewas
obtainedforbaselinedeterminations.Thestudyprotocolwas
approvedbytheHumanInvestigationReviewCommitteesof
theUniversityMedicalCentreUtrecht,andwritteninformed
consent was obtained from all participants.
2.2. TG Self-Measurements. Self-measurement of capillary
TG was performed with a TG-speciﬁc point-of-care testing
device (Accutrend GCT, Roche Diagnostics, Germany) [12–
14]. Subjects were instructed to wash and dry their hands
thoroughly before each measurement. With a lancing device,
a drop of blood (30µL) from the ﬁnger was obtained
which was applied to the TG test strip in the TG analyser.
Subsequently,TGconcentrationsweremeasuredbyaprocess
of dry chemistry and colorimetry. Participants measured
their capillary TG on three diﬀerent days at six standardized
time points: fasting, before and three hours after lunch
and dinner, and at bedtime. The results were recorded
in a diary. Subjects were requested to refrain from heavy
physical activity on the measurement days. Participants did
not receive recommendations concerning the frequency and
composition of the meals and were requested to use their
regular diet during the study. In case of one or more missing
measurements during a day, the data for that particular day
were not used for construction of an average diurnal TG
proﬁle. The mean diurnal TG proﬁle of 2 or 3 days was used
for statistical analysis.
The measurement range of the Accutrend GCT for
capillary TG is 0.80 to 6.86mmol/L. The Accutrend sys-
tem detects TG reliably, regardless of the nature of the
triglyceride-carrying lipoprotein species (chylomicrons or
VLDL particles) [15]. Variation coeﬃcients for diﬀerent cap-
illaryTGconcentrationsare3.3%forhighTG(6.12mmol/L)
and 5.3% for low TG (1.81mmol/L) [15]. The correlation
coeﬃcient between Accutrend capillary TG measurements
and plasma measurements according to enzymatic methods
is 0.94 [15]. Furthermore, in healthy lean subjects diurnal
capillary TG proﬁles correlate to postprandial lipemia
assessed by standardised oral fat-loading tests [13]. In
addition, diurnal triglyceridemia estimated with 6 measure-
ments over the day was not diﬀerent compared to hourly
measurements, suggesting that the chosen time points are
representative for the daylong study period [14].
2.3. Analytical Methods. Blood was collected at inclusion
after a 12 hours fast for measurement of plasma lipids,
apolipoproteins, insulin, and glucose. Cholesterol, plasma
triglyceride, and HDL cholesterol (obtained after precipita-
tion with dextran sulphate/MgCl2) were determined using
a Vitros 250 analyser (Johnson & Johnson Rochester, NY,
USA). Plasma apo B was measured by nephelometry using
apo B monoclonal antibodies (Behring Diagnostics NV,
OSAN14/15).PlasmaapoAIwasmeasuredbynephelometry
using apo AI monoclonal antibodies (Behring Diagnostics
NV, OUED 14/15). Plasma glucose was measured by glucose
oxidase dry chemistry (Vitros GLU slides) and colorimetry
and insulin was measured by competitive radio immunoas-
say with polyclonal antibodies. The HOMA-IR index (=
glucose (mmol/L) ∗insulin (mU/L)/22.5) was calculated for
estimation of insulin sensitivity.
2.4. Genotyping Procedures. Genotypes were determined as
describedpreviously[16].Abloodsampleforpolymorphism
analysis was obtained from each patient in the morning after
aminimumof8hfasting.GenomicDNAwasextractedfrom
white blood cells using silica gel polymer [17]. Reactions
were conducted using DNA ampliﬁcation in a ﬁnal volume
of 15µL containing 0.75µmol/L of each primer, 75µmol/L
of each NTP, 2ng/µL DNA, 1.5mmol/L MgCl2, 75mmol/L
Tris-HCl (pH 9.0), 20mmol/L (NH4)2SO4, 5mmol/L KCl,
and 0.2U/µL Netzyme DNA polymerase (Need, SL, Valen-
cia, Spain). The DNA was ampliﬁed for 40 cycles with
denaturation at 94◦C for 90s (PTC-100 thermal cycler, MI
Research). The polymerase chain reaction (PCR) products
underwent electrophoresis using 2% agarose gel. DNA was
visualized with ethidium bromide staining. The region of
the AT1R located between nucleotides 423 and 1278 of the
cDNA was ampliﬁed using oligonucleotides 5 -GGC TTT
GCT TTG TCT TGT TG and 5 -AAT GCT TGT AGC
CAA AGT CAC CT as sense and antisense primers, respec-
tively. Ampliﬁcation was conducted as described above. The
A1166C and C573T polymorphisms of the AT1R gene were
analyzed simultaneously by PCR using the technique which
is described in detail elsewhere [18].
2.5. Statistical Analysis. Values are given as mean ± standard
deviation (SD). Comparisons between CAD index patients
and healthy relatives were performed with Student’s t-
test. Comparisons between the diﬀerent genotypes of the
polymorphisms were performed with one-way ANOVA with
BonferronicorrectionforparametricdataandPearson’sChi-
squarefornonparametricdata.InthecaseofTG,insulin,and
HOMA index, calculations were performed after logarithmic
transformation; however, untransformed concentrations are
shown in the text, tables, and ﬁgures. Calculations ofInternational Journal of Vascular Medicine 3
TG-AUCs were performed with GraphPad Prism version
3.0 for Windows (GraphPad Software, San Diego, Calif,
USA) using nonlogarithmic transformed TG concentrations.
Postprandial lipemia was deﬁned as the incremental area
under the capillary TG curve after correction for fasting
capillary TG (dTG-AUC). For statistical analysis, PASW
version 18.0 was used. Statistical signiﬁcance was reached
when P<0.05 (two sided).
3. Results
A total of 82 subjects were included. Sixteen of them were
normocholesterolemic CAD patients, and there were 66
healthy relatives. The frequency of the T-allele for the C573T
gene polymorphisms was 65%. The C-allele for the A1166C
gene polymorphisms showed a frequency of 60%. No
signiﬁcant diﬀerences in allele distribution between patients
and family members were found. All polymorphisms were
in Hardy–Weinberg equilibrium. Baseline characteristics
for the A1166C and C573T polymorphisms are shown in
Tables 1 and 2, respectively. No signiﬁcant diﬀerences were
found among the diﬀerent A1166C polymorphisms, but
the BMI was signiﬁcantly diﬀerent among the C573T
polymorphisms (P = 0.047).
Postprandial lipemia expressed as the dTG-AUC was
signiﬁcantly higher in homozygous carriers of the 1166-
Ca l l e l e( 9 .39 ± 8.36mM∗h/L) compared to homozygous
carriers of the A-allele (2.02 ± 6.20 mM∗h/L) (P<0.05).
Postprandial lipemia in carriers of the CA polymorphism of
the A1166C gene was 3.65 ± 7.42mM∗h/L, which was inter-
mediatetotheCCandAApolymorphisms,withoutreaching
statistical signiﬁcance (Figure 1). Postprandial lipemia was
similar for the diﬀerent C573T gene polymorphisms ranging
from 4.05 ± 9.54mM∗h/L for the CC polymorphism,
3.82 ± 4.75mM∗h/L for the CT polymorphism, to 2.17 ±
7.00mM∗h/L for the TT polymorphism (Figure 2).
4. Discussion
It has been suggested that 40% of the variation in triglyceride
concentrations in the population is caused by genetic
heritability [19]. This study shows for the ﬁrst time increased
postprandial lipemia in homozygous carriers of the 1166-
C allele of the AT1R gene. It should be noted that the
number of subjects in this study was small and only seven
subjects were homozygous carriers of the 1166-C-allele.
Despite the fact that fasting TG, the strongest determinant
of postprandial lipemia, was similar for the groups, the
CC-group showed an exaggerated postprandial response.
Disturbances of lipid metabolism are frequent in patients
with hypertension, metabolic syndrome, and cardiovascu-
lar disease; together they share numerous susceptibility
genes [6]. Two experimental studies demonstrated increased
contraction of human arteries in homozygous carriers of
the 1166-C allele [20, 21]. In hypertensive patients with
metabolic syndrome, the presence of the CC1166 genotype
was a risk factor for central obesity and dyslipidemia [9].
Furthermore, the C-allele of the A1166C polymorphism
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Figure 1: Diurnal capillary triglyceride (cTG) patterns for A1166C
polymorphisms. Fasting cTG was similar for the three diﬀerent
polymorphisms, but homozygous carriers of the 1166-C allele
showed a signiﬁcantly increased incremental area under the cap-
illary triglyceride curve compared to homozygous carriers of the
1166-A allele (P<0.05).
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Figure 2: Diurnal capillary triglyceride patterns for C573T poly-
morphisms. No signiﬁcant diﬀerences for the polymorphisms were
found in the incremental area under the capillary triglyceride curve
as a marker for postprandial lipemia.
has been associated with a decreased endothelial response
to statin treatment measured with brachial artery ﬂow-
mediated dilation [22]. The C-allele also predisposes to an
increased risk for stroke, especially in combination with
hypertension [23]. It is known that endothelial function
becomes impaired by increased TG concentrations after
an oral fat-loading test [24, 25]. All these data suggest
that the A1166C polymorphism of the AT1R gene shares4 International Journal of Vascular Medicine
Table 1: Baseline characteristics for A1166C polymorphisms. Data are given as mean ± standard deviation unless stated otherwise.
AA (N = 34) CA (N = 41) CC (N = 7) P-value
Age (years) 43.8 ±16.54 1 .3 ±11.05 0 .0 ±12.1N S
Male gender 18 (53%) 22 (54%) 3 (43%) NS
CAD 9 (26%) 5 (12%) 2 (29%) NS
BMI 25.1 ± 3.42 5 .6 ±4.72 6 .5 ± 2.9N S
Waist (cm) 91.8 ±11.39 2 .0 ±15.69 6 .0 ±11.8N S
Systolic RR (mmHg) 126.6 ± 10.6 124.2 ±14.5 127.9 ± 10.4N S
Diastolic RR (mmHg) 82.8 ± 9.28 2 .1 ±8.18 4 .3 ± 6.1N S
Total cholesterol (mmol/L) 5.5 ±0.95 .3 ±1.05 .6 ±0.6N S
LDL-C (mmol/L) 3.7 ±0.83 .5 ±0.93 .6 ±0.7N S
HDL-C (mmol/L) 1.26 ±0.33 1.18 ±0.30 1.35 ±0.40 NS
Plasma TG (mmol/L) 1.34 ±0.62 1.37 ±0.70 1.29 ±0.79 NS
ApoB (g/L) 0.99 ±0.23 0.93 ±0.23 0.94 ±0.20 NS
ApoA-I (g/L) 1.37 ±0.19 1.33 ±0.23 1.30 ±0.28 NS
HOMA-IR 2.31 ±1.41 2.51 ±1.96 2.70 ±1.75 NS
CAD: coronary artery disease, BMI: body mass index, RR: blood pressure, TG: triglyceride, Apo: apolipoprotein, HOMA-IR: homeostatic model assessment.
Table 2: Baseline characteristics for C573T polymorphisms. Data are given as mean ± standard deviation unless stated otherwise.
CC (N = 29) CT (N = 34) TT (N = 19) P-value
Age (years) 45.0 ±10.44 0 .7 ±15.44 4 .3 ±15.0N S
Male gender 13 (44.8%) 20 (58.8%) 10 (52.6%) NS
CAD 6 (20.7%) 4 (14.7%) 5 (26.3%) NS
BMI 26.6 ±5.02 5 .5 ±3.62 3 .7 ±2.5 P = 0.047
Waist (cm) 95.2 ±15.79 2 .0 ±12.88 8 .2 ±10.5N S
Systolic RR (mmHg) 125.6 ±10.9 125.3 ±14.9 125.8 ±11.2N S
Diastolic RR (mmHg) 84.0 ±7.58 0 .6 ±8.08 4 .2 ±9.8N S
Total cholesterol (mmol/L) 5.6 ±1.05 .2 ±0.85 .4 ±1.0N S
LDL-C (mmol/L) 3.8 ±1.03 .4 ±0.83 .5 ±0.9N S
HDL-C (mmol/L) 1.29 ±0.34 1.17 ±0.29 1.24 ±0.34 NS
Plasma TG (mmol/L) 1.27 ±0.55 1.43 ±0.73 1.33 ±0.73 NS
ApoB (g/L) 0.97 ±0.22 0.95 ±0.22 0.94 ±0.26 NS
ApoA-I (g/L) 1.35 ±0.21 1.34 ±0.23 1.35 ±0.20 NS
HOMA-IR 2.77 ±2.34 2.45 ±1.40 2.45 ±1.72 NS
CAD: coronary artery disease, BMI: body mass index, RR: blood pressure, TG: triglyceride, Apo: apolipoprotein, HOMA-IR: homeostatic model assessment.
susceptibility with common disorders seen in metabolic
syndrome like postprandial lipemia.
The C573T polymorphism did not show any diﬀerences
in postprandial lipemia. A possible explanation is that it does
notinﬂuencetheaminoacidsequenceoftheencodedprotein
although this polymorphism is located in the coding region
of the gene [21]. In contrast, the A1166C polymorphism
is located in a nontranslated region of the AT1R gene
but it has been suggested to be in linkage disequilibrium
with another, yet-unknown, functional mutation thus ex-
plaining the multiple associations of this polymorphism
with several diseases. However, contradictory results have
also been found which could not conﬁrm the association
of the A1166C polymorphism with metabolic syndrome,
hypertension,orcardiovasculardisease[26,27].Inonestudy
the A1166C polymorphism was not related to triglyceride
concentrations, but this study was performed in a Hong
Kong Chinese population and only two subjects with the
CC genotype could be identiﬁed [28]. A very recent study
comprising more than 100,000 individuals did not ﬁnd an
association between the A1166C polymorphism and blood
lipids, including TG [8]. However, the authors did not study
speciﬁcally postprandial lipemia.
5. Conclusions
Although contribution of the diﬀerent genes seems small,
there is evidence that genetic variations have a cumulative
eﬀect on the cardiovascular risk [18, 29, 30] and that
genetic variations modulate the eﬀect of environmental
factors on cardiovascular risk [31]. With the availability of
easy and quick gene mapping, it might be possible in the
future to genetically classify patients according to their risk,International Journal of Vascular Medicine 5
before the disease phenotype is manifest. This might lead
to preventive treatment of patients in the high-risk classes,
thusdiminishing diseaseburdenandpreventingunnecessary
treatment of low-risk patients. In conclusion, we report that
postprandial lipemia is increased in homozygous carriers of
the C-1166 polymorphism of the AT1R gene. No association
was found between postprandial lipemia and the C573T
polymorphism.
References
[1] J. E. Hokanson and M. A. Austin, “Plasma triglyceride level
is a risk factor for cardiovascular disease independent of
high-density lipoprotein cholesterol level: a meta-analysis of
population-basedprospectivestudies,”JournalofCardiovascu-
lar Risk, vol. 3, no. 2, pp. 213–219, 1996.
[2] N. Sarwar, J. Danesh, G. Eiriksdottir et al., “Triglycerides
and the risk of coronary heart disease: 10 158 Incident
cases among 262 525 participants in 29 Western prospective
studies,” Circulation, vol. 115, no. 4, pp. 450–458, 2007.
[3] S. Mora, N. Rifai, J. E. Buring, and P. M. Ridker, “Fasting
compared with nonfasting lipids and apolipoproteins for
predicting incident cardiovascular events,” Circulation, vol.
118, no. 10, pp. 993–1001, 2008.
[ 4 ]S .B a n s a l ,J .E .B u r i n g ,N .R i f a i ,S .M o r a ,F .M .S a c k s ,a n dP .
M. Ridker, “Fasting compared with nonfasting triglycerides
and risk of cardiovascular events in women,” Journal of the
American Medical Association, vol. 298, no. 3, pp. 309–316,
2007.
[5] B. G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjærg-
Hansen, “Nonfasting triglycerides and risk of myocardial
infarction, ischemic heart disease, and death in men and
women,” Journal of the American Medical Association, vol. 298,
no. 3, pp. 299–308, 2007.
[ 6 ]P .K i s f a l i ,N .P o l g ´ a r ,E .S ´ afr´ any et al., “Triglyceride level
aﬀecting shared susceptibility genes in metabolic syndrome
and coronary artery disease,” Current Medicinal Chemistry,
vol. 17, no. 30, pp. 3533–3541, 2010.
[7] P. Perez-Martinez, J. Lopez-Miranda, F. Perez-Jimenez, and J.
M.Ordovas,“Inﬂuenceofgeneticfactorsinthemodulationof
postprandial lipemia,” Atherosclerosis Supplements, vol. 9, no.
2, pp. 49–55, 2008.
[8] T. M. Teslovich, K. Musunuru, A. V. Smith et al., “Biological,
clinical and population relevance of 95 loci for blood lipids,”
Nature, vol. 466, no. 7307, pp. 707–713, 2010.
[9] L. M. Procopciuc, A. Sitar-Tˇ aut, D. Pop, D. A. Sitar-Tˇ aut,
I. Olteanu, and D. Zdrenghea, “Renin angiotensin system
polymorphisms in patients with metabolic syndrome (MetS),”
European Journal of Internal Medicine, vol. 21, no. 5, pp. 414–
418, 2010.
[10] G. R. Dagenais, J. Pogue, K. Fox, M. L. Simoons, and S. Yusuf,
“Angiotensin-converting-enzyme inhibitors in stable vascular
disease without left ventricular systolic dysfunction or heart
failure: a combined analysis of three trials,” Lancet, vol. 368,
no. 9535, pp. 581–588, 2006.
[11] G.RemuzziandP.Ruggenenti,“Overviewofrandomisedtrials
of ACE inhibitors,” Lancet, vol. 368, no. 9535, pp. 555–556,
2006.
[12] J. P. H. Van Wijk, M. C. Castro Cabezas, C. J. M. Halkes,
a n dD .W .E r k e l e n s ,“ E ﬀects of diﬀerent nutrient intakes on
daytime triacylglycerolemia in healthy, normolipemic, free-
livingmen,”AmericanJournalofClinicalNutrition,vol.74,no.
2, pp. 171–178, 2001.
[13] M. Castro Cabezas, C. J. M. Halkes, S. Meijssen, A. J. H. H.
M. Van Oostrom, and D. W. Erkelens, “Diurnal triglyceride
proﬁles: a novel approach to study triglyceride changes,”
Atherosclerosis, vol. 155, no. 1, pp. 219–228, 2001.
[14] A. J. H. H. M. Van Oostrom, C. Castro, J. Ribalta et al.,
“Diurnal triglyceride proﬁles in healthy normolipidemic male
subjectsareassociated toinsulinsensitivity,body composition
and diet,” European Journal of Clinical Investigation, vol. 30,
no. 11, pp. 964–971, 2000.
[15] C. Luley, G. Ronquist, W. Reuter et al., “Point-of-care testing
of triglycerides: evaluation of the accutrend triglycerides
system,” Clinical Chemistry, vol. 46, no. 2, pp. 287–291, 2000.
[16] J. Redon, M. Luque-Otero, N. Martell et al., “Renin-angiot-
ensin system gene polymorphisms: relationship with blood
pressure and microalbuminuria in telmisartan-treated hyper-
tensive patients,” Pharmacogenomics Journal,v o l .5 ,n o .1 ,p p .
14–20, 2005.
[17] L. Tilzer, S. Thomas, and R. F. Moreno, “Use of silica gel
polymer for DNA extraction with organic solvents,” Analytical
Biochemistry, vol. 183, no. 1, pp. 13–15, 1989.
[ 1 8 ]F .J .C h a v e s ,J .M .P a s c u a l ,E .R o v i r a ,M .E .A r m e n g o d ,a n d
J. Redon, “Angiotensin II AT1 receptor gene polymorphism
and microalbuminuria in essential hypertension,” American
Journal of Hypertension, vol. 14, no. 4, pp. 364–370, 2001.
[19] A. M. Shearman, J. M. Ordovas, L. A. Cupples et al., “Evidence
for a gene inﬂuencing the TG/HDL-C ratio on chromosome
7q32.3-qter: a genome-wide scan in the Framingham Study,”
Human Molecular Genetics, vol. 9, no. 9, pp. 1315–1320, 2000.
[20] C. Amant, M. Hamon, C. Bauters et al., “The angiotensin
II type 1 receptor gene polymorphism is associated with
coronary artery vasoconstriction,” Journal of the American
College of Cardiology, vol. 29, no. 3, pp. 486–490, 1997.
[21] P. P. Van Geel, Y. M. Pinto, A. A. Voors et al., “Angiotensin II
type 1 receptor A1166C gene polymorphism is associated with
an increased response to angiotensin II in human arteries,”
Hypertension, vol. 35, no. 3, pp. 717–721, 2000.
[22] M. Kiliszek, B. Burzy´ nska, G. Styczy´ nski, M. Macia ¸g, D.
Rabczenko, and G. Opolski, “A1166C polymorphism of the
angiotensin AT1 receptor (AT1R) gene alters endothelial
response to statin treatment,” Clinical Chemistry and Labora-
tory Medicine, vol. 45, no. 7, pp. 839–842, 2007.
[23] S. Rubattu, E. Di Angelantonio, R. Stanzione et al., “Gene
polymorphisms of the renin-angiotensin-aldosterone system
and the risk of ischemic stroke: a role of the A1166C/AT1 gene
variant,” Journal of Hypertension, vol. 22, no. 11, pp. 2129–
2134, 2004.
[24] D. C. Daskalova, G. D. Kolovou, D. B. Panagiotakos, N. D.
Pilatis, and D. V. Cokkinos, “Increase in aortic pulse wave
velocity is associated with abnormal postprandial triglyceride
response,” Clinical Cardiology, vol. 28, no. 12, pp. 577–583,
2005.
[25] R. A. Vogel, M. C. Corretti, and G. D. Plotnick, “Eﬀect of
a single high-fat meal on endothelial function in healthy
subjects,” American Journal of Cardiology, vol. 79, no. 3, pp.
350–354, 1997.
[26] G. K. Andrikopoulos, D. J. Richter, E. W. Needham et al.,
“The paradoxical association of common polymorphisms of
the renin-angiotensin system genes with risk of myocardial
infarction,” European Journal of Cardiovascular Prevention and
Rehabilitation, vol. 11, no. 6, pp. 477–483, 2004.
[27] P. Strazzullo, R. Iacone, L. Iacoviello et al., “Genetic variation
in the renin-angiotensin system and abdominal adiposity in
men: the olivetti prospective heart study,” Annals of Internal
Medicine, vol. 138, no. 1, pp. 17–23, 2003.6 International Journal of Vascular Medicine
[28] G. N. Thomas, B. Tomlinson, J. C. N. Chan, J. E. Sanderson,
C. S. Cockram, and J. A. J. H. Critchley, “Renin-angiotensin
system gene polymorphisms, blood pressure, dyslipidemia,
and diabetes in Hong Kong Chinese: a signiﬁcant association
of the ACE insertion/deletion polymorphism with type 2
diabetes,” Diabetes Care, vol. 24, no. 2, pp. 356–361, 2001.
[29] P. Marques-Vidal, V. Bongard, J. B. Ruidavets, J. Fauvel, B.
Perret, and J. Ferri` eres, “Eﬀect of apolipoprotein E alleles
and angiotensin-converting enzyme insertion/deletion poly-
morphisms on lipid and lipoprotein markers in middle-aged
men and in patients with stable angina pectoris or healed
myocardial infarction,” American Journal of Cardiology, vol.
92, no. 9, pp. 1102–1105, 2003.
[30] D. Petroviˇ c, M. Zorc, V. Kaniˇ c, and B. Peterlin, “Interaction
between gene polymorphisms of renin-angiotensin system
and metabolic risk factors in premature myocardial infarc-
tion,” Angiology, vol. 52, no. 4, pp. 247–252, 2001.
[31] Y. Tabara, K. Kohara, J. Nakura, and T. Miki, “Risk factor-
gene interaction in carotid atherosclerosis: eﬀect of gene poly-
morphisms of renin-angiotensin system,” Journal of Human
Genetics, vol. 46, no. 5, pp. 278–284, 2001.